Comparative Pharmacology
Head-to-head clinical analysis: LARYNG O JET KIT versus LIDOPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARYNG O JET KIT versus LIDOPEN.
LARYNG-O-JET KIT vs LIDOPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine, a local anesthetic, stabilizes neuronal membranes by inhibiting sodium ion channels, blocking initiation and conduction of nerve impulses. Epinephrine causes vasoconstriction via alpha-1 adrenergic receptor activation, reducing systemic absorption of lidocaine and prolonging local effect.
Lidocaine is a sodium channel blocker, stabilizing neuronal membranes by inhibiting the influx of sodium ions, thereby preventing the propagation of action potentials and producing local anesthesia.
Topical administration via laryngeal spray: 1-2 sprays (10-20 mg) to the larynx and pharynx, repeated as needed up to every 1-2 hours, not to exceed 8 sprays per 24 hours.
Lidocaine 2% topical gel: Apply 1-2 grams (approximately 5-10 cm ribbon) to affected area every 4-6 hours as needed, not to exceed 5 grams per day. For infiltration anesthesia: 1% solution, 0.5-5 mL injected locally; maximum 4.5 mg/kg.
None Documented
None Documented
Terminal elimination half-life is 1.5–2 hours (mean 1.8 h), necessitating frequent dosing for sustained effect.
1.5–2 hours (terminal); prolonged in hepatic impairment
Renal excretion of unchanged drug accounts for approximately 70% of elimination, with 30% undergoing hepatic metabolism and biliary/fecal elimination.
Renal (10% unchanged; 80% as metabolites), biliary/fecal (10%)
Category C
Category C
Local Anesthetic
Local Anesthetic